MiniMed Partners Abbott on Dual Glucose-Ketone Sensors
66d ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
medical-devicesdiabetes-care
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
MiniMed announced a strategic partnership with Abbott Laboratories on 3 June 2026 to co-develop and commercialize a first-of-its-kind dual glucose-ketone continuous monitoring sensor. The multi-year agreement aims to integrate MiniMed's proprietary ketone sensing technology with Abbott's established FreeStyle Libre glucose monitoring platform, targeting a combined market opportunity exceeding $12 billion annually. This move signals a significant escalation in the competition to serve the expanding metabolic health and therapeutic ketosis markets beyond traditional diabetes care.
The partnership arrives as the global continuous glucose monitoring market is projected to grow from $8.1 billion in 2025 to over $15.3 billion by 2030, according to industry analysts. Therapeutic ketosis, for managing conditions like epilepsy and as an adjunct therapy for certain cancers, represents a nascent but rapidly expanding adjacent market. The last major technological leap in consumer metabolic monitoring was Dexcom's introduction of its G7 sensor in 2022, which achieved real-time glucose readings with a 30-minute warm-up period. Current macro conditions, with stable interest rates, have facilitated increased R&D spending in the medtech sector, allowing for more ambitious collaborative projects between established players and innovators.
The catalyst for this specific collaboration is the recent FDA draft guidance issued in Q1 2026, which created a more streamlined regulatory pathway for multi-analyte Class II medical devices. This guidance effectively reduced the anticipated time-to-market for combined sensor systems, making the development partnership financially viable for both entities. Abbott's extensive manufacturing scale and distribution network provides the necessary infrastructure to bring a novel dual sensor to a mass market quickly.
Abbott's Diabetes Care segment reported $4.5 billion in revenue for fiscal year 2025, representing 11% year-over-year growth. The company's FreeStyle Libre system alone serves over 5 million users globally. The total addressable market for ketone monitoring is estimated at $1.2 billion, growing at a compound annual growth rate of 18%. MiniMed, a privately held firm, secured $150 million in Series C funding in late 2025, valuing the company at approximately $850 million pre-partnership.
A comparative analysis shows the stark difference in user base: Abbott's Libre has millions of active users, while dedicated ketone monitoring systems from competitors like Keto-Mojito currently serve an estimated 250,000 users worldwide. The partnership aims to use Abbott's manufacturing capability, which produces over 100 million sensors annually, to achieve economies of scale previously unavailable for ketone sensing technology. The joint development budget for the first 18 months is set at $300 million.
The partnership is net positive for Abbott Laboratories (ABT), as it bolsters its flagship FreeStyle Libre platform against increasing competition from Dexcom (DXCM) and Medtronic (MDT). It allows ABT to defend its market share by adding a new feature set without the need for a costly acquisition. Dexcom faces increased competitive pressure, as its current product roadmap is focused solely on glucose sensing, potentially creating a feature gap. Medical device component manufacturers like TE Connectivity (TEL) and Sensirion could see increased orders for advanced biosensor elements.
A key risk is execution; integrating two distinct biosensing technologies into a single, miniaturized device presents significant engineering challenges that could delay launch. Regulatory approval, while eased, is not guaranteed for the combined product. Flow data indicates institutional investors are increasing exposure to the broader metabolic health sector, with ETFs like IHI (iShares U.S. Medical Devices ETF) seeing increased volume following the announcement. Short interest in pure-play glucose monitoring firms has ticked up slightly.
The first major catalyst is the expected FDA pre-submission meeting for the dual sensor in Q4 2026. This meeting will determine the final clinical trial requirements and regulatory pathway. Investors should monitor Abbott's Q3 2026 earnings call on 18 October for any updates on the integration timeline and revised R&D expenditure guidance for the Diabetes Care segment.
Key levels to watch include ABT's stock price holding above its 200-day moving average of $118.50, a level it has maintained for the past quarter. For the sector, the performance of the IHI ETF against the broader health care sector (XLV) will indicate if the theme has legs. The next significant event is the J.P. Morgan Healthcare Conference in January 2027, where a prototype demonstration is anticipated.
A dual glucose-ketone sensor is a single wearable device capable of continuously measuring both glucose and ketone levels in bodily fluid, typically interstitial fluid. This provides a more comprehensive metabolic picture for users managing diabetes, pursuing ketogenic diets, or using therapeutic ketosis for medical conditions. The technology represents a convergence of two previously separate monitoring fields into one integrated platform.
The partnership is strategically positive for ABT as it enhances its competitive moat in the diabetes care market without a dilutive acquisition. It allows Abbott to use its existing manufacturing and distribution for a new product line. Analysts project a potential 2-4% uplift to ABT's revenue growth rate by 2028 if the product launch is successful, though near-term R&D costs may slightly pressure margins.
The primary competitor will be Dexcom (DXCM), which currently dominates the high-end CGM market but lacks a ketone sensing product. Other competitors include Keto-Mojito, a specialist in ketone monitoring, and Roche Diabetes Care. The partnership effectively creates a new product category, so incumbent players will need time to develop a competitive response, giving Abbott and MiniMed a first-mover advantage.
The partnership accelerates the convergence of glucose and ketone monitoring, creating a new product category within the $12 billion metabolic health market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.